See Full Report below….
About Broad Street Alerts:
Big opportunities in Small Cap’s
Broad Street Alerts recent profiles and track record, 153% in verifiable potential gains for our
Members in the last 3 small cap alerts alone!
February 10th, 2016- (NASDAQ: BONT) opened $1.65/share hit a high of $3.00/share within 30 days our members gains- 83%
March 7th, 2016-(NYSE-MKT: FSI) opened at .91/share and hit 1.10/share within 5 days for gains of 21% for our members.
March 24th, 2016- (NASDAQ: ICLD) opened at $.77/share it a high of $1.15/share within 2 days for gains of 49%
For our members.
These are numbers that make traders drool. Any trader in any market would fall all over themselves to see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business.
We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.
***Get our small cap profiles, special situation and watch alerts in real time.
We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.
Article:
Chesapeake Energy (NYSE: CHK) 34.4% HIGHER; shares gaining for a second session after the company entered an amended credit agreement on Monday. In addition, Tudor Pickering upgraded the stock to Hold today.
Highpower International, Inc. (Nasdaq: HPJ) 26.7% HIGHER; announced this morning that the Company recently began to receive orders, and started shipping lithium polymer batteries to DJI, a globally recognized manufacturer of commercial and recreational unmanned aerial vehicles, or drones.
Horizon Pharma (Nasdaq: HZNP) 24.1% LOWER; provided first-half 2016 net sales and adjusted EBITDA guidance today. First-quarter 2016 net sales guidance would represent 79 percent year-over-year growth at the midpoint; second-quarter 2016 net sales guidance would represent 35 percent year-over-year growth at the midpoint
Denbury Resources Inc. (NYSE: DNR) 23.6% HIGHER; posting another session of gains as oil & gas names ramp higher.
Azure Midstream Partners, LP (NYSE: AZUR) 22.0% HIGHER; see Denbury Resources above. Shares are also rebounding after falling from above $2.50 just about a month ago.
SM Energy Company (NYSE: SM) 19.6% HIGHER; another energy name rising today amid a strong 2016 showing so far for the stock.
EP Energy Corporation (NYSE: EPE) 17.9% HIGHER; looking to add to a 3.6 percent gain on Monday. The stock is down just 7 percent for the year, but also down 68 percent versus the same period lasty year.
Och-Ziff Capital Management (NYSE: OZM) 16.4% LOWER; The Justice Department is pushing Och-Ziff Capital Management to plead guilty in a criminal case and seeking $400 million in civil sanctions related to alleged bribery overseas, according to Dow Jones.
T2 Biosystems, Inc. (Nasdaq: TTOO) 11.8% LOWER; announced preliminary financial results for the first quarter of 2016. The Company expects that Q1 revenue will be approximately $1 million, with approximately 40% of the revenue being derived from the sale of consumable tests for T2Candida and 60% from research projects. As of March 31, 2016, seven additional hospitals had completed installation and verification in Q1 and began using T2Candida to test patients bringing the total number of hospitals that have begun testing patients with T2Candida to 16.
Net 1 UEPS Technologies, Inc. (Nasdaq: UEPS) 8.6% LOWER; paring gains from Monday after it announced that it has entered into an agreement with International Finance Corporation and certain funds managed by IFC Asset Management Company pursuant to which IFC has agreed to subscribe for 9.98 million shares of the Company’s common stock at a subscription price of $10.79 per share, for total proceeds of $107.7 million.
Viking Therapeutics, Inc (Nasdaq: VKTX) 7.5% LOWER; highlighted positive data from a Phase 1b clinical trial of VK2809 in subjects with mild hypercholesterolemia, presented at the 65th Annual Scientific Session & Expo of the American College of Cardiology (ACC). The results demonstrated substantial and clinically meaningful reductions in subjects’ low-density lipoprotein cholesterol (LDL-C), triglycerides, and atherogenic proteins lipoprotein-a and apolipoprotein B following 14 days of treatment.
Source: Street Insider
